Open-label Study to Assess Increasing Levels of NAD+(Nicotinamide Adenine Dinucleotide)
NCT ID: NCT03707652
Last Updated: 2018-10-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
8 participants
INTERVENTIONAL
2018-03-12
2018-05-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Oral NAD+ Precursors Administration on Blood NAD+ Concentration in Healthy Adults
NCT05517122
NAD Supplementation Study
NCT03310034
Effects of NAD3 Supplementation on Biomarkers of Aging
NCT04276948
Effectiveness of Qualia NAD+ Supplementation on Intracellular NAD Levels
NCT06505967
Measurement of NAD+ Synthesis in Human Skeletal Muscle
NCT04905446
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants receive assessments of blood tests, vital signs, body weight with completion of questionnaires.
The primary objective of the study is to identify the ideal dosage of an oral supplement to increase whole blood NAD+ levels in adults.
The secondary objective of the study is to monitor for safety from a change in fasting blood chemistry panel parameters after three day's dosing compared to cycle baseline.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort A (oral supplement A)-2 capsules
Oral supplement A (2 capsules) administered daily for 3 days
Oral supplement A
1, 2 or 4 capsules daily of oral supplement A for 3 days
Cohort A (oral supplement B)-4 capsules
Oral supplement B (4 capsules) administered daily for 3 days
Oral supplement B
4 capsules daily of oral supplement B for 3 days
Cohort A (oral supplement C)-2 capsules
Oral supplement C (2 capsules) administered daily for 3 days
Oral supplement C
1,2 or 4 capsules daily of oral supplement C for 3 days
Cohort A (oral supplement A)-1 or 4 capsules
Oral supplement A (1 or 4 capsules) administered daily for 3 days
Oral supplement A
1, 2 or 4 capsules daily of oral supplement A for 3 days
Cohort A (oral supplement D)-1 or 2 tablets
Oral supplement D (1 or 2 tablets) administered daily for 3 days
Oral supplement D
1 or 2 tablets daily of oral supplement D for 3 days
Cohort A (oral supplement D) or combination with supplement C
Oral supplement D (1 or 2 tablets) or combination with oral supplement C (2 or 4 capsules) administered daily for 3 days
Oral supplement D
1 or 2 tablets daily of oral supplement D for 3 days
Oral Supplement D in combination with oral supplement C
1 or 2 tablets of oral supplement D in combination with 2 or 4 capsules of oral supplement C for 3 days
Cohort B (oral supplement B)-4 capsules
Oral supplement B (4 capsules) administered daily for 3 days
Oral supplement B
4 capsules daily of oral supplement B for 3 days
Cohort B (oral supplement C)-2 capsules
Oral supplement C (2 capsules) administered daily for 3 days
Oral supplement C
1,2 or 4 capsules daily of oral supplement C for 3 days
Cohort B (oral supplement A)-2 capsules
Oral supplement A (2 capsules) administered daily for 3 days
Oral supplement A
1, 2 or 4 capsules daily of oral supplement A for 3 days
Cohort B (oral supplement C)- 1 or 4 capsules
Oral supplement C (1 or 4 capsules) administered daily for 3 days
Oral supplement C
1,2 or 4 capsules daily of oral supplement C for 3 days
Cohort B (oral supplement D)-1 or 2 tablets
Oral supplement D (1 or 2 tablets) administered daily for 3 days
Oral supplement D
1 or 2 tablets daily of oral supplement D for 3 days
Cohort B(oral supplement D) or combination with supplement C
Oral supplement D (1 or 2 tablets) or combination with oral supplement C (2 or 4 capsules) administered daily for 3 days
Oral supplement D
1 or 2 tablets daily of oral supplement D for 3 days
Oral Supplement D in combination with oral supplement C
1 or 2 tablets of oral supplement D in combination with 2 or 4 capsules of oral supplement C for 3 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral supplement A
1, 2 or 4 capsules daily of oral supplement A for 3 days
Oral supplement B
4 capsules daily of oral supplement B for 3 days
Oral supplement C
1,2 or 4 capsules daily of oral supplement C for 3 days
Oral supplement D
1 or 2 tablets daily of oral supplement D for 3 days
Oral Supplement D in combination with oral supplement C
1 or 2 tablets of oral supplement D in combination with 2 or 4 capsules of oral supplement C for 3 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to follow verbal and written study directions in English
* Adult men and women between age 30-80 years (inclusive)
* Women of reproductive potential will practice contraception during the Investigation
* Body Mass Index (BMI) between 18.5 and 35 kg/m2
* Must not be taking or be willing to stop taking any supplements containing any form of niacin for seven days prior to baseline and for the duration of the study.
* Must not be using or be willing to stop use of any "100%" or higher niacin fortified foods from seven days prior to screening visit and for the duration of the investigation
* Able to maintain consistent diet and lifestyle habits throughout the study
* Volunteers with chronic but stable and well controlled medical conditions (i.e., hypertension controlled by a consistent dose of medication for a minimum of six months; chronic use of consistent dose of blood-thinning medication; diet-controlled Type II diabetes) may participate at the discretion of the PI or Sub-I.
* Willing and able to provide fasting blood samples
* Able to attend scheduled visits at the Life Extension Clinical Research (LECR) facility
Exclusion Criteria
* Use of statin drugs
* Having used any tobacco product or used a recreational drug in the past 6 months
* Medically complicated \[i.e., diabetes requiring insulin; uncontrolled hypertension (blood pressure readings at screening/baseline \> 140 systolic or \> 90 diastolic on two consecutive readings); etc.\] at the discretion of the PI or Sub-I
* Having abnormal screening laboratory test values or other lab test result(s) that would preclude study participation in the judgment of the PI or Sub-I
* Woman who is pregnant, nursing, or planning a pregnancy. Non-pregnant status of women of childbearing potential will be confirmed during each Day 3 Cycle LECR visit (Wednesday or Thursday) via serum pregnancy test.
* Currently, or within the past 30 days, enrolled in a different clinical investigation
* Inability to provide a venous blood sample
* Unable to refrain from any alcohol consumption for the duration of the study
* Unable or unwilling to provide written informed consent for participation in study
30 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Supplement Formulators, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrew Swick, Ph.D
Role: PRINCIPAL_INVESTIGATOR
LIfe Extension
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Life Extension Clinical Research, Inc.
Fort Lauderdale, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kennedy BK, Berger SL, Brunet A, Campisi J, Cuervo AM, Epel ES, Franceschi C, Lithgow GJ, Morimoto RI, Pessin JE, Rando TA, Richardson A, Schadt EE, Wyss-Coray T, Sierra F. Geroscience: linking aging to chronic disease. Cell. 2014 Nov 6;159(4):709-13. doi: 10.1016/j.cell.2014.10.039.
Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. 2012;7(7):e42357. doi: 10.1371/journal.pone.0042357. Epub 2012 Jul 27.
Verdin E. NAD(+) in aging, metabolism, and neurodegeneration. Science. 2015 Dec 4;350(6265):1208-13. doi: 10.1126/science.aac4854.
Revollo JR, Grimm AA, Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol. 2007 Mar;23(2):164-70. doi: 10.1097/MOG.0b013e32801b3c8f.
Yang H, Lavu S, Sinclair DA. Nampt/PBEF/Visfatin: a regulator of mammalian health and longevity? Exp Gerontol. 2006 Aug;41(8):718-26. doi: 10.1016/j.exger.2006.06.003. Epub 2006 Jul 13.
Gross CJ, Henderson LM. Digestion and absorption of NAD by the small intestine of the rat. J Nutr. 1983 Feb;113(2):412-20. doi: 10.1093/jn/113.2.412.
Knip M, Douek IF, Moore WP, Gillmor HA, McLean AE, Bingley PJ, Gale EA; European Nicotinamide Diabetes Intervention Trial Group. Safety of high-dose nicotinamide: a review. Diabetologia. 2000 Nov;43(11):1337-45. doi: 10.1007/s001250051536.
Airhart SE, Shireman LM, Risler LJ, Anderson GD, Nagana Gowda GA, Raftery D, Tian R, Shen DD, O'Brien KD. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS One. 2017 Dec 6;12(12):e0186459. doi: 10.1371/journal.pone.0186459. eCollection 2017.
Dellinger RW, Santos SR, Morris M, Evans M, Alminana D, Guarente L, Marcotulli E. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. NPJ Aging Mech Dis. 2017 Nov 24;3:17. doi: 10.1038/s41514-017-0016-9. eCollection 2017.
Trammell SA, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, Li Z, Abel ED, Migaud ME, Brenner C. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016 Oct 10;7:12948. doi: 10.1038/ncomms12948.
de Picciotto NE, Gano LB, Johnson LC, Martens CR, Sindler AL, Mills KF, Imai S, Seals DR. Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice. Aging Cell. 2016 Jun;15(3):522-30. doi: 10.1111/acel.12461. Epub 2016 Mar 11.
Mills KF, Yoshida S, Stein LR, Grozio A, Kubota S, Sasaki Y, Redpath P, Migaud ME, Apte RS, Uchida K, Yoshino J, Imai SI. Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell Metab. 2016 Dec 13;24(6):795-806. doi: 10.1016/j.cmet.2016.09.013. Epub 2016 Oct 27.
ClinicalTrials.gov. Effect of
Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington (DC): National Academies Press (US); 1998. Available from http://www.ncbi.nlm.nih.gov/books/NBK114310/
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CL094
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.